Natural Products Insider is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
HomeBusiness ResourcesBusiness OperationsLabs/TestingChromaDex Announces Top Line Results of its Second Human Clinical Trial

ChromaDex Announces Top Line Results of its Second Human Clinical Trial

<p>ChromaDex Corp. (NASDAQ:CDXC announced today that the initial results of its second human clinical study of NIAGEN<sup>&reg;</sup> nicotinamide riboside chloride (NR) have confirmed NR significantly and sustainably raises the co-enzyme nicotinamide adenine dinucleotide (NAD+) in 140 healthy human volunteers over 8-weeks.</p>
TAGS: Healthy Living Ingredients Business Resources
Hide comments
account-default-image
user not logged in

More information about text formats

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish
Related
cbd testing.jpg
CBD, delta-8 THC and other cannabinoids’ place in sport and drug testing
Jul 28, 2021
cognitive creative_1449792248.jpg
Cognitive function and focus trending
May 26, 2021
FeatureImage-Alzchem-1540x800-0421.jpg
Paid Content
Creapure® - GRAS certified and Amazon compliant for peace of mind – infographic
Apr 16, 2021
Trojan flag.png
Federal bill introduced to change hemp definition to 1% THC
Apr 01, 2021